Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...106107108109110111112113114115116...136137»
  • ||||||||||  Journal:  Microfluidic devices for disease modeling in muscle tissue. (Pubmed Central) -  Jul 7, 2020   
    Muscle-on-a-chip technology has drastically improved and serves as a drug screening platform for many muscular diseases such as muscular dystrophy, tendinosis, fibromyalgia, mitochondrial myopathy, and myasthenia gravis. This review seeks to communicate the gaps in knowledge of current muscular disease models and highlight the power of microfluidic devices in enabling researchers to better understand disease pathology and provide high throughput screening of therapeutics for muscular myopathies.
  • ||||||||||  Tirosint (levothyroxine) / IBSA Institute Biochemical SA, azathioprine orodispersible / Generic mfg.
    [VIRTUAL] A Case of Respiratory Failure with Recurrent Intubations in a Patient with Severe Hypothyroidism (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_7404;    
    Patient was started on azathioprine, pyridostigmine, and steroids initially for myasthenia...Following initiation of levothyroxine therapy, ten days post-intubation, improvement in tongue and lip swelling were noted and patient was successfully extubated...Symptoms of bulbar and respiratory muscle weakness, hypoventilation and hypoxia characteristic of myasthenia gravis can overlap with those of myxedema leading to difficulty ascertaining the etiology of respiratory failure. Prompt recognition of myxedema coma is crucial due to associated high mortality rates if treatment is not instituted.
  • ||||||||||  [VIRTUAL] A Rare Case of Shared Paralysis (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_6862;    
    Treatment modalities for all forms of Flavivirus encephalitis are the same with ongoing research demonstrating some role of ribavirin, interferon alpha and IVIG. Prognosis is usually guarded which emphasizes more on the early recognition and timely initiation of appropriate treatment.
  • ||||||||||  [VIRTUAL] Not in the Clear: A Case of Recurrent Thymoma (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_6113;    
    There are, however, cases of recurrent thymoma 10-15 years post-resection with the longest time to recurrence noted in the literature to be 32 years. While cases such as this patient's are uncommon, recurrent thymoma should be kept within the differential of patients reporting respiratory or chest abnormalities despite being outside of the typical recurrence timeframe, particularly because earlier diagnosis of recurrence leads to improved outcomes.
  • ||||||||||  carboplatin / Generic mfg., Keytruda (pembrolizumab) / Merck (MSD), pemetrexed / Generic mfg.
    [VIRTUAL] An Eye-Opening Complication: A Rare Case of Myasthenia Gravis Secondary to Immune Checkpoint Inhibitors (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_3999;    
    The diagnosis of immune-related myasthenia gravis is challenging as many symptoms are subtle and can mimic more common medical conditions. Early recognition and treatment of immune checkpoint inhibitor-related myasthenia gravis is critical as this form of the disease is more aggressive than typical autoimmune myasthenia gravis with several fatal cases reported in the literature.
  • ||||||||||  prednisone / Generic mfg.
    [VIRTUAL] Spontaneous Super Mesenteric Artery Hemorrhage in a Patient with Myasthenia Gravis (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_3104;    
    He was treated with IVIG for 6 days followed by high dose prednisone with improvement in his neurological exam...In addition, patient had additional risk factors present for spontaneous SMA rupture including advanced age, male sex and atherosclerosis 4 . In patients who receive treatment with IVIG, there should be close monitoring for adverse reactions, particularly coagulopathy.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] A Fatal Case of Multisystem Organ Dysfunction Secondary to Immune Check Point Inhibitor Use (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_3064;    
    Corticosteroids are first line of treatment. For steroid resistant cases, immunomodulatory agents, such as infliximab, other TNF inhibitors, anti-thymocyte globulin, or intravenous immunoglobulin and plasmapharesis may be required (1).
  • ||||||||||  Journal, Checkpoint inhibition:  Myasthenia Gravis Induced by Immune Checkpoint Inhibitors. (Pubmed Central) -  Jul 5, 2020   
    Prognosis is poor, as 13 patients died after MG. MG is a rare immune-related AE that must be rapidly evoked and treated in case of neurological symptoms emerging after immunotherapy.
  • ||||||||||  Firdapse (amifampridine) / BioMarin, Catalyst Pharma
    Journal:  Amifampridine for the Management of Lambert-Eaton Myasthenic Syndrome: A New Take on an Old Drug. (Pubmed Central) -  Jul 5, 2020   
    Relevance to Patient Care and Clinical Practice: With an improved stability profile and decreased dose variability, amifampridine will likely assume the role of first-line management of LEMS. Amifampridine has been shown to improve symptoms of LEMS and is generally well tolerated.
  • ||||||||||  [VIRTUAL] CONCURRENCE OF GVHD AND NON-INFECTIOUS NEUROLOGICAL COMPLICATIONS OF HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) -  Jul 3, 2020 - Abstract #EBMT2020EBMT_3316;    
    Furthermore, when analyzed according to a more natural distribution of occurrence borne out of stricter analysis criteria, a statistically significant association was established between the concurrence of GVHD and certain NCs. This study underscores the importance of accurate reporting of GVHD in a precisely stratified HCT recipient population and increased awareness amongst treating physicians of the above-established associations.
  • ||||||||||  [VIRTUAL] CONCURRENCE OF GVHD AND NON-INFECTIOUS NEUROLOGICAL COMPLICATIONS OF HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) -  Jul 3, 2020 - Abstract #EBMT2020EBMT_3315;    
    Furthermore, when analyzed according to a more natural distribution of occurrence borne out of stricter analysis criteria, a statistically significant association was established between the concurrence of GVHD and certain NCs. This study underscores the importance of accurate reporting of GVHD in a precisely stratified HCT recipient population and increased awareness amongst treating physicians of the above-established associations.
  • ||||||||||  [VIRTUAL] CONCURRENCE OF GVHD AND NON-INFECTIOUS NEUROLOGICAL COMPLICATIONS OF HEMATOPOIETIC CELL TRANSPLANTATION (ePoster Area) -  Jul 3, 2020 - Abstract #EBMT2020EBMT_3314;    
    Furthermore, when analyzed according to a more natural distribution of occurrence borne out of stricter analysis criteria, a statistically significant association was established between the concurrence of GVHD and certain NCs. This study underscores the importance of accurate reporting of GVHD in a precisely stratified HCT recipient population and increased awareness amongst treating physicians of the above-established associations.
  • ||||||||||  Journal:  Impetiginized, erosive plaques in a man with myasthenia gravis (Pubmed Central) -  Jul 2, 2020   
    Its identification sets the basis for precision medicine approaches based on "pharmacomiRs" as biomarkers of drug responsiveness in MG, promising to improve therapeutic success in a cost/effective manner. No abstract available
  • ||||||||||  cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Clinical, Review, Journal:  Myasthenia Gravis Can Have Consequences for Pregnancy and the Developing Child. (Pubmed Central) -  Jul 1, 2020   
    Rituximab should not be given during the last few months before conception and not during pregnancy...MG women should always give birth at hospitals with experience in newborn intensive care. MG does not represent a reason for not having children, and the patients should be supported in their wish of becoming pregnant.
  • ||||||||||  Clinical, Journal:  Phenotypic Differences in 2 Unrelated Cases Carrying Identical DOK7 Mutations. (Pubmed Central) -  Jun 29, 2020   
    Furthermore, the antibodies detected are predominately of the IgG1 subclass. These 2 cases illustrate the lack of phenotype-genotype correlation and the absence of geographic, genetic, and ethnic association in cases of LG CMS caused by DOK7 mutations.
  • ||||||||||  Journal:  Review of correlation between human parvovirus B19 and autoimmune disease etiology (Pubmed Central) -  Jun 28, 2020   
    Recent studies have confirmed that anti-B19-VP1u-IgG antibody is able to increase the activity of cytokines such as interleukin 1 (IL-1), tumor necrosis factor α (TNF-α), matrix metalloproteinase-9 (MMP9); PVB19 protein NS 1 and VP1u are capable of inducing the expression of IL-6; PVB19 can induce the production of Th17 cell-related cytokines, resulting in the decrease of IFN-gamma levels and the increase of IL-4 levels in plasma. In this paper, the structure of PVB19, the mechanism of human infection and the relationship between PVB19 and AIDs are summarized.
  • ||||||||||  Clinical, Journal:  Investigation of GHSR methylation levels in thymomas from patients with Myasthenia Gravis. (Pubmed Central) -  Jun 28, 2020   
    GHSR hypermethylation is not a pan-cancer marker or an early event in TAMG, but occurs in almost 1/4 of them and mainly from stage II onward. Subsequent studies are required to clarify the molecular pathways leading to GHSR hypermethylation in TAMG tissues and their relevance to disease progression.
  • ||||||||||  Journal:  Advances in the diagnosis and treatment of congenital myasthenic syndrome (Pubmed Central) -  Jun 28, 2020   
    Pharmacotherapy and symptomatic/supportive treatment are the main methods for the treatment of CMS, and antisense oligonucleotide technology has been proven to be beneficial for CHRNA 1-related CMS in animals. Since CMS is a group of increasingly recognized clinical and genetic heterogeneous diseases, an understanding of the latest knowledge and research advances in its clinical features, genetic research, and treatment helps to give early diagnosis and treatment as well as gain a deeper understanding of the pathogenesis of CMS, so as to make new breakthroughs in the treatment of CMS.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Clinical, Journal:  Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma. (Pubmed Central) -  Jun 27, 2020   
    To our knowledge, this is the first case of myasthenia gravis associated with pembrolizumab treatment against metastatic urothelial carcinoma. In this case, a relationship between immune-related adverse events associated with myasthenia gravis and tumor responses to pembrolizumab was suspected, because marked reductions in the sizes of some metastatic lesions were observed after the administration of only two courses of pembrolizumab.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, efgartigimod IV (ARGX-113 IV) / argenx, Broteio
    Journal:  Diagnosis and treatment of myasthenia gravis. (Pubmed Central) -  Jun 26, 2020   
    CBAs can lead to a significant reduction of seronegative patients, improving myasthenia gravis diagnostic process. New biological drugs offer innovative approaches to treat myasthenic patients with generalized disease, promising to change the paradigm of treatment and to significantly enhance therapeutic success within a precision medicine framework.
  • ||||||||||  Journal:  The Mary Walker effect: Mary Broadfoot Walker. (Pubmed Central) -  Jun 26, 2020   
    Further, she noted hypokalaemia during attacks of weakness in familial periodic paralysis, pioneering treatment with potassium chloride. Although Mary Walker practiced in a nonacademic setting and trained at a time when women were not allowed to train alongside men, she was the first to convincingly demonstrate three life-changing treatments in the field of neuromuscular medicine, a feat that few physicians of any era can claim.